Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR2C | P28335 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | SPR | P35270 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 3/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12188773 | 0.92 | KDM4E (0.45) | HTR2AHTR2CKCNH2DRD2SPR | |
| SCHEMBL1809430 | 0.86 | CACNA1B (0.50) | HTR2AHTR2CKCNH2DRD2MGLL | |
| SCHEMBL1811395 | 0.84 | HTR2A (0.49) | HTR2AHTR2CKCNH2DRD2SPR | |
| SCHEMBL1811520 | 0.78 | CACNA1B (0.50) | HTR2AHTR2CKCNH2DRD2AHR | |
| SCHEMBL1810369 | 0.77 | AHR (0.56) | HTR2AHTR2CKCNH2DRD2SPR | |
| SCHEMBL12099414 | 0.75 | HSD11B1 (0.46) | DRD2MGLLCACNA1B | |
| SCHEMBL1808433 | 0.73 | AHR (0.53) | HTR2AHTR2CKCNH2DRD2SPR | |
| SCHEMBL1806735 | 0.71 | AHR (0.47) | HTR2AHTR2CKCNH2DRD2SPR | |
| SCHEMBL12188601 | 0.71 | GAA (0.49) | SPRMGLL | |
| SCHEMBL22516913 | 0.71 | AHR (0.47) | DRD2SPRAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | HTR2A 661/4885HTR2C 771/4885KCNH2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.